Reports
Reports
Sale
The global traveller’s diarrhoea treatment market size is expected to grow at a CAGR of 6% during the forecast period of 2024-2032, driven by the rapidly growing tourism industry across the globe.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Traveller’s diarrhoea treatment is referred to a treatment for a condition in which intestine and stomach are infected, majorly caused by the unsanitary conditions while handling edibles. Traveller’s diarrhoea is characterised by frequent lose stools and abdominal cramps triggered by the consumption of contaminated food and unfiltered water.
The growth of traveller’s diarrhoea treatment market is being driven by the huge number of market players that offer significant competition. The market is stimulated by the growing emphasis on the adoption of the latest technological advancement by manufacturers of drugs, along with offering specialized distribution channels for drugs for the treatment of traveller’s diarrhoea.
Moreover, the latest product development to formulate specialized drugs and vaccines for the treatment of traveller’s diarrhoea with preventive effect, is shifting the market scenario for the treatment of traveller’s diarrhoea. In addition, the launch of new vaccine produced by the manufacturer is predicted to boost competition among the manufacturers of traveller’s diarrhoea treatment industry, further encouraging market growth.
The market can be categorized into segments like drug type, pathogen, age, route of administration, distribution channel, and region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Drug Type
Market Breakup by Pathogen
Market Breakup by Age
Market Breakup by Route of Administration
Market by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market growth is being driven by the rising number of regular flyers and booming tourism business in developing countries. The traveller’s diarrhoea treatment is crucial to the traveller’s itinerary and contributes significantly to the patient’s wellbeing while travelling abroad. In addition, the growing awareness among the masses about the traveller’s diarrhoea treatment is expected to provide impetus to the market growth of traveller’s diarrhoea treatment. The ease and convenience in acquiring the treatment drugs for traveller’s diarrhoea, along with the availability of over-the-counter medications is expected to provide lucrative opportunities for the growth of traveller’s diarrhoea treatment market.
The report gives a detailed analysis of the following key players in the global traveller’s diarrhoea treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Type |
|
Breakup by Pathogen |
|
Breakup by Age |
|
Breakup by Route of Administration |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Traveller’s Diarrhoea Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Traveller’s Diarrhoea Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Traveller’s Diarrhoea Epidemiology (2016-2031)
5.3 Europe Traveller’s Diarrhoea Epidemiology (2016-2031)
5.4 Asia-Pacific Traveller’s Diarrhoea Epidemiology (2016-2031)
5.5 Latin America Traveller’s Diarrhoea Epidemiology (2016-2031)
5.6 Middle East & Africa Traveller’s Diarrhoea Epidemiology (2016-2031)
6 Global Traveller’s Diarrhoea Treatment Market Overview
6.1 Global Traveller’s Diarrhoea Treatment Market Historical Value (2017-2023)
6.2 Global Traveller’s Diarrhoea Treatment Market Forecast Value (2024-2032)
7 Global Traveller’s Diarrhoea Treatment Market Landscape
7.1 Traveller’s Diarrhoea Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Traveller’s Diarrhoea Treatment: Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Pathogen
7.2.3 Analysis by Age
7.2.4 Analysis by Route of Administration
7.2.5 Analysis by Distribution Channel
8 Traveller’s Diarrhoea Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Traveller’s Diarrhoea Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Traveller’s Diarrhoea Treatment Market Segmentation
11.1 Global Traveller’s Diarrhoea Treatment Market by Drug Type
11.1.1 Market Overview
11.1.2 Oral Rehydration Therapy (ORS)
11.1.3 Antidiarrhoeal Agents
11.1.3.1 Antibiotics
11.1.3.2 Azithromycin
11.1.3.3 Ciprofloxacin
11.1.3.4 Quinolones
11.1.3.5 Rifaximin
11.1.3.6 Others
11.1.4 Vaccine/Prophylactics
11.1.5 Others
11.2 Global Traveller’s Diarrhoea Treatment Market by Pathogen
11.2.1 Market Overview
11.2.2 Bacteria
11.2.3 Viruses
11.2.4 Protozoa
11.2.5 Others
11.3 Global Traveller’s Diarrhoea Treatment Market by Age
11.3.1 Market Overview
11.3.2 Adult
11.3.3 Children
11.4 Global Traveller’s Diarrhoea Treatment Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.5 Global Traveller’s Diarrhoea Treatment Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacies
11.5.3 Retail Pharmacies
11.5.4 Online Pharmacies
11.5.5 Others
11.6 Global Traveller’s Diarrhoea Treatment Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Traveller’s Diarrhoea Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Traveller’s Diarrhoea Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Traveller’s Diarrhoea Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Traveller’s Diarrhoea Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Traveller’s Diarrhoea Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Bausch Health Companies Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 COSMO Pharmaceuticals
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Immuron Ltd.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Sanofi SA
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Bayer AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Merck & Co., Inc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Johnson & Johnson Services, Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Novartis AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Basilea Pharmaceutica Ltd
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Eli Lilly and Company
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Traveller’s Diarrhoea Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The global traveller’s diarrhoea treatment market size is expected to grow at a CAGR of 6% during the forecast period of 2024-2032.
The major drivers of the market include booming tourism business, rising awareness about the disease, rising demand from the developing regions, and the huge number of market players.
The key trends guiding the growth of the market include the availability of over-the-counter medications.
The major regions in the market include North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The drug types in the market include oral rehydration therapy (ORS), antidiarrhoeal agents, and vaccine/prophylactics, among others.
The pathogens in the market include bacteria, viruses, and protozoa, among others.
The age groups can be categorised into adult and children.
The routes of administration include oral and parenteral routes.
The distribution channels in the market include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The key players in the market include Bausch Health Companies Inc., COSMO Pharmaceuticals, Immuron Ltd., Sanofi SA, Bayer AG, Merck & Co., Inc, Johnson & Johnson Services, Inc., Novartis AG, Basilea Pharmaceutica Ltd, and Eli Lilly and Company.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.